Brandi L Cantarel1, Emmanuelle Waubant, Christel Chehoud, Justin Kuczynski, Todd Z DeSantis, Janet Warrington, Arun Venkatesan, Claire M Fraser, Ellen M Mowry. 1. From the *Baylor Institute for Immunology Research, Baylor Health, Dallas, TX; †Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD; ‡Department of Neurology, UCSF School of Medicine, San Francisco; and §Second Genome Inc, South San Francisco, CA; and ∥Department of Neurology, Johns Hopkins University School of Medicine; and ¶Department of Medicine, University of Maryland School of Medicine, Baltimore, MD.
Abstract
OBJECTIVES: Differences in gut bacteria have been described in several autoimmune disorders. In this exploratory pilot study, we compared gut bacteria in patients with multiple sclerosis and healthy controls and evaluated the influence of glatiramer acetate and vitamin D treatment on the microbiota. METHODS: Subjects were otherwise healthy white women with or without relapsing-remitting multiple sclerosis who were vitamin D insufficient. Patients with multiple sclerosis were untreated or were receiving glatiramer acetate. Subjects collected stool at baseline and after 90 days of vitamin D3 (5000 IU/d) supplementation. The abundance of operational taxonomic units was evaluated by hybridization of 16S rRNA to a DNA microarray. RESULTS: While there was overlap of gut bacterial communities, the abundance of some operational taxonomic units, including Faecalibacterium, was lower in patients with multiple sclerosis. Glatiramer acetate-treated patients with multiple sclerosis showed differences in community composition compared with untreated subjects, including Bacteroidaceae, Faecalibacterium, Ruminococcus, Lactobacillaceae, Clostridium, and other Clostridiales. Compared with the other groups, untreated patients with multiple sclerosis had an increase in the Akkermansia, Faecalibacterium, and Coprococcus genera after vitamin D supplementation. CONCLUSIONS: While overall bacterial communities were similar, specific operational taxonomic units differed between healthy controls and patients with multiple sclerosis. Glatiramer acetate and vitamin D supplementation were associated with differences or changes in the microbiota. This study was exploratory, and larger studies are needed to confirm these preliminary results.
OBJECTIVES: Differences in gut bacteria have been described in several autoimmune disorders. In this exploratory pilot study, we compared gut bacteria in patients with multiple sclerosis and healthy controls and evaluated the influence of glatiramer acetate and vitamin D treatment on the microbiota. METHODS: Subjects were otherwise healthy white women with or without relapsing-remitting multiple sclerosis who were vitamin D insufficient. Patients with multiple sclerosis were untreated or were receiving glatiramer acetate. Subjects collected stool at baseline and after 90 days of vitamin D3 (5000 IU/d) supplementation. The abundance of operational taxonomic units was evaluated by hybridization of 16S rRNA to a DNA microarray. RESULTS: While there was overlap of gut bacterial communities, the abundance of some operational taxonomic units, including Faecalibacterium, was lower in patients with multiple sclerosis. Glatiramer acetate-treated patients with multiple sclerosis showed differences in community composition compared with untreated subjects, including Bacteroidaceae, Faecalibacterium, Ruminococcus, Lactobacillaceae, Clostridium, and other Clostridiales. Compared with the other groups, untreated patients with multiple sclerosis had an increase in the Akkermansia, Faecalibacterium, and Coprococcus genera after vitamin D supplementation. CONCLUSIONS: While overall bacterial communities were similar, specific operational taxonomic units differed between healthy controls and patients with multiple sclerosis. Glatiramer acetate and vitamin D supplementation were associated with differences or changes in the microbiota. This study was exploratory, and larger studies are needed to confirm these preliminary results.
Authors: T Z DeSantis; P Hugenholtz; N Larsen; M Rojas; E L Brodie; K Keller; T Huber; D Dalevi; P Hu; G L Andersen Journal: Appl Environ Microbiol Date: 2006-07 Impact factor: 4.792
Authors: Susan E Pryde; Sylvia H Duncan; Georgina L Hold; Colin S Stewart; Harry J Flint Journal: FEMS Microbiol Lett Date: 2002-12-17 Impact factor: 2.742
Authors: Christopher T Brown; Austin G Davis-Richardson; Adriana Giongo; Kelsey A Gano; David B Crabb; Nabanita Mukherjee; George Casella; Jennifer C Drew; Jorma Ilonen; Mikael Knip; Heikki Hyöty; Riitta Veijola; Tuula Simell; Olli Simell; Josef Neu; Clive H Wasserfall; Desmond Schatz; Mark A Atkinson; Eric W Triplett Journal: PLoS One Date: 2011-10-17 Impact factor: 3.240
Authors: Vincent C Lombardi; Kenny L De Meirleir; Krishnamurthy Subramanian; Sam M Nourani; Ruben K Dagda; Shannon L Delaney; András Palotás Journal: J Nutr Biochem Date: 2018-04-19 Impact factor: 6.048
Authors: Anne-Katrin Pröbstel; Xiaoyuan Zhou; Ryan Baumann; Sven Wischnewski; Michael Kutza; Olga L Rojas; Katrin Sellrie; Antje Bischof; Kicheol Kim; Akshaya Ramesh; Ravi Dandekar; Ariele L Greenfield; Ryan D Schubert; Jordan E Bisanz; Stephanie Vistnes; Khashayar Khaleghi; James Landefeld; Gina Kirkish; Friederike Liesche-Starnecker; Valeria Ramaglia; Sneha Singh; Edwina B Tran; Patrick Barba; Kelsey Zorn; Johanna Oechtering; Karin Forsberg; Lawrence R Shiow; Roland G Henry; Jennifer Graves; Bruce A C Cree; Stephen L Hauser; Jens Kuhle; Jeffrey M Gelfand; Peter M Andersen; Jürgen Schlegel; Peter J Turnbaugh; Peter H Seeberger; Jennifer L Gommerman; Michael R Wilson; Lucas Schirmer; Sergio E Baranzini Journal: Sci Immunol Date: 2020-11-20